Avid Bioservices, Inc. Highlights New Bioassay Capabilities to Support Phase III and Commercial-Stage Development Programs

Published: May 14, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TUSTIN, CA--(Marketwired - May 14, 2013) - Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today announced that its recent success in qualifying an antibody-dependent, cell-mediated cytotoxicity (ADCC) bioassay will be highlighted in a poster presentation at IBC's 23rd International Intensive Symposium Development, Validation and Maintenance of Biological Assays Conference to be held in Seattle, Washington, May 14-16, 2013. Avid customized a novel nuclear factor of activated T cells (NFAT) potency assay to evaluate and characterize monoclonal antibodies and with extensive testing yielding positive results, has implemented this as part of its standard portfolio of Quality Control (QC) lot release and stability testing capabilities. The latest bioassay success is another example of the variety of bioassays developed at Avid to characterize the activity and potency of therapeutic proteins, including monoclonal antibodies.

The poster will be on display in the poster and exhibit hall, May 14-15, 2013 at the Grand Hyatt Seattle:

"Customization, Scale-up and Qualification of an Antibody-dependent Cell-mediated Cytotoxicity (ADCC) Bioassay"
Location: Poster Board #7

"This is an important milestone for Avid that allows us to offer simple and robust bioassays that avoid much of the variability seen with classical methods," said Connie Chang, director of Process Science for Avid Bioservices. "This latest bioassay provides greater sensitivity and improved reliability, allowing the client to evaluate process changes more effectively than with traditional ADCC-based bioassays. The assay performance has remained consistent throughout the optimization, qualification and scale-up steps, and now serves as a reliable bioassay to support lot release and stability testing for Phase III clinical trials and commercialization of their well characterized biologic."

For additional information on IBC's Development, Validation and Maintenance of Biological Assays Conference, please visit: http://www.ibclifesciences.com/bioassays/overview.xml

About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support the manufacture of cGMP clinical phase and commercial products. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include GMP clinical and commercial product manufacturing, purification, bulk packaging, final product filling, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.